Nantahala Capital Management, LLC - Nov 6, 2024 Form 3 Insider Report for Evoke Pharma Inc (EVOK)

Role: 10%+ Owner
Signature: /s/ Taki Vasilakis, Chief Compliance Officer, Nantahala Capital Management, LLC
Stock symbol: EVOK
Transactions as of: Nov 6, 2024
Transactions value $: $0
Form type: 3
Date filed: 11/15/2024, 04:31 PM
Previous filing: Jun 18, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	EVOK	Common Stock						148K	Nov 6, 2024	See footnote	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	EVOK	Pre-Funded Warrants	Nov 6, 2024	Common Stock	434K	$0.00	See footnote	F1
holding	EVOK	Series A Common Stock Purchase Warrants	Nov 6, 2024	Common Stock	117K	$8.16	See footnote	F1
holding	EVOK	Series B Common Stock Purchase Warrants	Nov 6, 2024	Common Stock	245K	$8.16	See footnote	F1
holding	EVOK	Series C Common Stock Purchase Warrants	Nov 6, 2024	Common Stock	117K	$8.16	See footnote	F1
holding	EVOK	Amended Series A Common Stock Purchase Warrants	Nov 6, 2024	Common Stock	159K	$0.01	See footnote	F1
holding	EVOK	Amended Series C Common Stock Purchase Warrants	Nov 6, 2024	Common Stock	251K	$0.01	See footnote	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Nantahala Capital Management, LLC ("NCM"), an investment adviser to certain private funds and managed accounts (the "NCM Investors") that hold the Evoke Pharma, Inc. ("Issuer") securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.

Content

Nantahala Capital Management, LLC ("NCM"), an investment adviser to certain private funds and managed accounts (the "NCM Investors") that hold the Evoke Pharma, Inc. ("Issuer") securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.